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Genotype-phenotype relationship is the mainstay of 
studies in medical genetics. In the light of genetic counseling 
for example and prenatal diagnosis in particular, the knowledge 
becomes even more important for decision-making during 
pregnancy termination. The most common Mendelian-inherited 
disease, thalassemia, causes by defective synthesis of either α- 
or β-globin chain. Key pathologic determinant deserves 
mention that is the continuing production of the counterpart 
globin chain in excess--overproduction of β-globin in case of 
α-thalassemia and α-globin for β-thalassemia. 
β-Thalassemia mutations 
Mutations cause null output from β-globin gene designated 
β0-thalassemia while those causing partial reduction of the 
output define β+-thalassemia. The most prevalent 
β+-thalassemia in Thailand is βE hemoglobin [1] (varying from 
3% in the central and upto 50-70% in the Northeast) occurred as 
a result of substitution mutation in codon 26 leading to glutamic 
instead of lysine residue (c.76G>A according to recommended 
nomenclature [2], in addition activation of cryptic splice site 
culminating in nonproductive mRNA [3]. The combination of 
βE together with β0- or other β+-thalassemia constitutes the 
majority of β -thalassemic patients. Their peripheral blood 
contains no Hb A (α2 β2) but Hb F (α2 2), Hb E (α2β
E2) and Hb A2 (α2  2).  However, predicting clinical 
severity of these patients are not always simple. In fact, clinical 
presentation could be classified as mild, moderate and severe 
forms according to scoring system [4]. 
 Detailed data presented here are as published elsewhere 
[5]. Figure 1 demonstrates severity of various forms of 
β-thalassemia mutations with βE (917 patients). Obviously, all 
patients with mutation at -28 A to G are clinically mild and the 
mutation considered β+-thalassemia. The remaining categories 
classified as β0-thalassemia mutations are codon 41/42 
(-TTCT) (or c.121_124delTTCT), codon 17 (A>T) (c.48A>T), 
IVS II-654(C>T,) IVS I-5(G>C), IVS I-1(G>T) and other. 
Noteworthy, all β0-thalassemia mutations when inherited with 
βE result in unpredictable severity. 
 
Coinheritance with α-thalassemia 
 Considering the high frequency of α-thalassemia in this 
region, Table 1 illustrates the tendency of having milder forms 
if there coexists whether deletion of one of both α-globin 
genes—α3.7, α4.2 or αSEAandnondeletion as αConstant 
Spring and αPakse. Both forms of α-thalassemia ameliorate the 
symptoms due to reduced output from the mutated genes 
thereby decreasing the excess α-globin chains in β-thalassemia. 
However, coinheritance together with αSEA-thalassemia (both 
α-globin gene deleted) in Table 1 is not the exception because 
this patient carries codon 121(G>T) (c.361G>T) mutation 
when inherited as heterozygote alone is enough to produce 
severe disease (dominant β-thalassemia) [6]. The concepts are 
appreciated by considering triplicated α-globin genes expected 
to increase α-globin chain output indeed aggravate the diseases 
[7]. 
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 Using multinomial regression of severity outcome and 
predictors as β-thalassemia mutations, α-globin genotypes as 
well as sex, age and clinical centers where patients were 
recruited, the results indicate that types of β0-thal mutations do 
not grossly confer significant difference in terms of clinical 
severity whereas identity of α-globin genotypes coinherited 
differentially affects in severity modification. Author therefore 
supports the notion that β0-thalassemia/Hb E patients with 
apparent mild symptoms should be screened for α-thalassemia 
[7]. Other covariates such as age and sex have small influence. 
With the exception of patients with IVS-I-1(G > T), they tend to 
be moderate rather than severe when compare to other 
β0-thalassemia mutations. 
 
 
 
Genetic modifiers 
 Large deletions, dominant and unknown β-thalassemia 
mutations are excluded. Still, β0-thalassemia/Hb E patients 
with comparable β0-mutations without any forms of 
α-thalassemia virtually manifest variable phenotypes. With the 
advent of genome-wide association studies, other major loci 
modifying disease severity (mild vs severe) becomes appear i.e. 
BCL11A, HBS1L-MYB intergenic region and polymorphisms 
within β-globin locus [8-10]. These three major loci are 
believed to modify disease severity via modulation of 
percentage of fetal hemoglobin (%Hb F). Other genetic loci 
responsible for remaining proportions of variations in %Hb F 
expectedly exist in the genome, this is termed missing 
heritability or hidden heritability (11). 
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